B7-H3 nanoCAR-T cells

B7-H3 nanoCAR-T cells are an experimental cellular immunotherapy consisting of T cells engineered to express a chimeric antigen receptor (CAR) that utilizes a nanobody (single-domain antibody) as the extracellular antigen-binding domain. These cells specifically target B7-H3 (CD276), a transmembrane protein overexpressed in various solid tumors, including glioblastoma, while having limited expression in healthy tissues. Developed by researchers at the Vrije Universiteit Brussel (VUB), this "nanoCAR" architecture aims to leverage the small size and low immunogenicity of nanobodies compared to traditional single-chain variable fragment (scFv)-based CARs. Preclinical studies in glioblastoma models demonstrated potent anti-tumor activity but also highlighted risks of on-target, off-tumor toxicity due to the high sensitivity of the nanobody-based receptor to low-level B7-H3 expression on healthy tissues.

Other names

B7-H3-targeting nanobody-based CAR-T cellsB-7-H3-targeting nanobody-based CAR-T cellsB 7-H3-targeting nanobody-based CAR-T cellsB7-H3 nanobody-based CAR-T cellsB-7-H3 nanobody-based CAR-T cellsB 7-H3 nanobody-based CAR-T cells